Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats

Toxicology and Applied Pharmacology

Volumn 254, Issue 3, 2011, Pages 267-279

  Nurmio, Mirja ^a   Joki, Henna ^a   Kallio, Jenny ^a   Määttä, Jorma A ^a   Väänänen, H Kalervo ^a   Toppari, Jorma ^a   Jahnukainen, Kirsi ^b,c   Laitala Leinonen, Tiina ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Bone resorption; Imatinib; Osteoblast; Osteoclast; Receptor tyrosine kinase

Indexed keywords

ABELSON KINASE; CATHEPSIN K; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN C FMS; PROTEIN L 11; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RIBOSOME PROTEIN; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE GROWTH; BONE MINERAL; BONE PLATE; BONE REMODELING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENCHONDRAL OSSIFICATION; ENZYME INHIBITION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; RADIOGRAPHY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TREATMENT DURATION;

ANIMALS; BONE DEVELOPMENT; BONE RESORPTION; MALE; OSTEOGENESIS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR PROTEIN-TYROSINE KINASES;

RATTUS;

EID: 79960054838     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.04.019     Document Type: Article

References (40)

1. Ando W., Hashimoto J., Nampei A., Tsuboi H., Tateishi K., Ono T., Nakamura N., Ochi T., Yoshikawa H. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA). J. Bone Miner. Metab. 2006, 24:274-282.
2. Berman E., Nicolaides M., Maki R.G., Fleisher M., Chanel S., Scheu K., Wilson B.A., Heller G., Sauter N.P. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 2006, 354:2006-2013.
3. Bianchi M.L., Baim S., Bishop N.J., Gordon C.M., Hans D.B., Langman C.B., Leonard M.B., Kalkwarf H.J. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatr Nephrol. 2010, 25:37-47.
4. Brannan C.I., Lyman S.D., Williams D.E., Eisenman J., Anderson D.M., Cosman D., Bedell M.A., Jenkins N.A., Copeland N.G. Steel-Dickie mutation encodes a c-kit ligand lacking transmembrane and cytoplasmic domains. Proc. Natl. Acad. Sci. U S A 1991, 88:4671-4674.
5. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., Lyons A.B. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132.
6. El Hajj Dib I., Gallet M., Mentaverri R., Sevenet N., Brazier M., Kamel S. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur. J. Pharmacol. 2006, 551:27-33.
7. Fiedler J., Etzel N., Brenner R.E. To go or not to go: migration of human mesenchymal progenitor cells stimulated by isoforms of PDGF. J. Cell. Biochem. 2004, 93:990-998.
8. Fierro F., Illmer T., Jing D., Schleyer E., Ehninger G., Boxberger S., Bornhauser M. Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif. 2007, 40:355-366.
9. Fitter S., Dewar A.L., Kostakis P., To L.B., Hughes T.P., Roberts M.M., Lynch K., Vernon-Roberts B., Zannettino A.C. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008, 111:2538-2547.
10. Grey A., O'Sullivan S., Reid I.R., Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N. Engl. J. Med. 2006, 355:2494-2495.
11. Halleen J.M., Hentunen T.A., Karp M., Kakonen S.M., Pettersson K., Väänänen H.K. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J. Bone Miner. Res. 1998, 13:683-687.
12. Hiraga T., Nakamura H. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. Int. J. Cancer 2009, 124:215-222.
13. Hock J.M., Canalis E. Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts. Endocrinology 1994, 134:1423-1428.
14. Hofstetter W., Wetterwald A., Cecchini M.C., Felix R., Fleisch H., Mueller C. Detection of transcripts for the receptor for macrophage colony-stimulating factor, c-fms, in murine osteoclasts. Proc. Natl. Acad. Sci. U S A 1992, 89:9637-9641.
15. Horner A., Bord S., Kemp P., Grainger D., Compston J.E. Distribution of platelet-derived growth factor (PDGF). A chain mRNA, protein, and PDGF-alpha receptor in rapidly forming human bone. Bone 1996, 19:353-362.
16. Jamsa T., Jalovaara P., Peng Z., Väänänen H.K., Tuukkanen J. Comparison of three-point bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone 1998, 23:155-161.
17. Jin L., Tabe Y., Konoplev S., Xu Y., Leysath C.E., Lu H., Kimura S., Ohsaka A., Rios M.B., Calvert L., Kantarjian H., Andreeff M., Konopleva M. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 2008, 7:48-58.
18. Kalkwarf H.J., Gilsanz V., Lappe J.M., Oberfield S., Shepherd J.A., Hangartner T.N., Huang X., Frederick M.M., Winer K.K., Zemel B.S. Tracking of bone mass and density during childhood and adolescence. J. Clin. Endocrinol. Metab. 2010, 95:1690-1698.
19. Kent D., Copley M., Benz C., Dykstra B., Bowie M., Eaves C. Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway. Clin. Cancer Res. 2008, 14:1926-1930.
20. Kimoto T., Inoue M., Kawa K. Growth deceleration in a girl treated with imatinib. Int. J. Hematol. 2009, 89:251-252.
21. Kumar S., Mishra N., Raina D., Saxena S., Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol. Pharmacol. 2003, 63:276-282.
22. Laitala-Leinonen T., Rinne R., Saukko P., Väänänen H.K., Rinne A. Cystatin B as an intracellular modulator of bone resorption. Matrix Biol. 2006, 25:149-157.
23. Li B., Boast S., de los Santos K., Schieren I., Quiroz M., Teitelbaum S.L., Tondravi M.M., Goff S.P. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat. Genet. 2000, 24:304-308.
24. Lipton A., Campbell-Baird C., Harvey H., Kim C., Demers L., Costa L. Phase I trial of zoledronic acid+imatinib mesylate (Gleevec) in patients with bone metastases. Am. J. Clin. Oncol. 2010, 33:75-78.
25. Liu F., Malaval L., Aubin J.E. Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation. J. Cell Sci. 2003, 116:1787-1796.
26. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) method. Methods 2001, 25:402-408.
27. Lotinun S., Evans G.L., Turner R.T., Oursler M.J. Deletion of membrane-bound steel factor results in osteopenia in mice. J. Bone Miner. Res. 2005, 20:644-652.
28. Mariani S., Giona F., Basciani S., Brama M., Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008, 372:111-112.
29. McLeod M.J. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 1980, 22:299-301.
30. Nurmio M., Toppari J., Zaman F., Andersson A.M., Paranko J., Soder O., Jahnukainen K. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int. J. Androl. 2007, 30:366-376. discussion 376.
31. O'Sullivan S., Naot D., Callon K., Porteous F., Horne A., Wattie D., Watson M., Cornish J., Browett P., Grey A. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J. Bone Miner. Res. 2007, 22:1679-1689.
32. O'Sullivan S., Naot D., Callon K.E., Watson M., Gamble G.D., Ladefoged M., Karsdal M.A., Browett P., Cornish J., Grey A. Imatinib mesylate does not increase bone volume in vivo. Calcif. Tissue Int. 2011, 88:16-22.
33. Säämänen A.K., Salminen H.J., Dean P.B., De Crombrugghe B., Vuorio E.I., Metsaranta M.P. Osteoarthritis-like lesions in transgenic mice harboring a small deletion mutation in type II collagen gene. Osteoarthritis Cartilage 2000, 8:248-257.
34. Säämänen A.M., Hyttinen M., Vuorio E. Analysis of arthritic lesions in the Del1 mouse: a model for osteoarthritis. Methods Mol. Med. 2007, 136:283-302.
35. Thoren L.A., Liuba K., Bryder D., Nygren J.M., Jensen C.T., Qian H., Antonchuk J., Jacobsen S.E. Kit regulates maintenance of quiescent hematopoietic stem cells. J. Immunol. 2008, 180:2045-2053.
36. Vandyke K., Dewar A.L., Fitter S., Menicanin D., To L.B., Hughes T.P., Zannettino A.C. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009, 23:2155-2159.
37. Vandyke K., Fitter S., Dewar A.L., Hughes T.P., Zannettino A.C. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010, 115:766-774.
38. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., Sudo T., Shultz L.D., Nishikawa S. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990, 345:442-444.
39. Zayas J., Spassov D.S., Nachtman R.G., Jurecic R. Murine hematopoietic stem cells and multipotent progenitors express truncated intracellular form of c-kit receptor. Stem Cells Dev. 2008, 17:343-353.
40. Zhang Z., Chen J., Jin D. Platelet-derived growth factor (PDGF)-BB stimulates osteoclastic bone resorption directly: the role of receptor beta. Biochem. Biophys. Res. Commun. 1998, 251:190-194.